AldoxorubicinHCl
- CAS No.
- 1361563-03-2
- Chemical Name:
- AldoxorubicinHCl
- Synonyms
- D10384;CS-1410;CHEMBL2107827;Aldoxorubicin•Aldoxorubicin hydrochloride, 10 mM in DMSO;ALDOXORUBICIN HCL; CHEMBL2107827; 1361563-03-2; D10384
- CBNumber:
- CB24844455
- Molecular Formula:
- C37H43ClN4O13
- Molecular Weight:
- 787.22
- MDL Number:
- MFCD25371995
- MOL File:
- 1361563-03-2.mol
| FDA UNII | S098K6HGD9 |
|---|
AldoxorubicinHCl Chemical Properties,Uses,Production
Uses
Aldoxorubicin (INNO-206) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin hydrochloride (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
in vivo
Aldoxorubicin hydrochloride (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor[1]. Aldoxorubicin hydrochloride (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study[2]. Aldoxorubicin hydrochloride (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models[3].
References
[1] Walker L, et al. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm. 2012 Oct 15;436(1-2):825-32. DOI:10.1016/j.ijpharm.2012.07.043
[2] Graeser R, et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2010 F DOI:10.1007/s10637-008-9208-2
[3] Eric Sanchez, et al. Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206. Clin Cancer Res.2012 18; 3856.
[4] Kratz, F. INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies. Current Bioactive Compounds, 2011, 7(1): 33-38(6)
AldoxorubicinHCl Preparation Products And Raw materials
Raw materials
Preparation Products
AldoxorubicinHCl Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32268 | 58 |
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38664 | 58 | |
| WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd. | 17702719238 17702719238 | sales@sun-shinechem.com | China | 1042 | 64 |
| Cckinase, Inc. | +1 (732)236-3202 | sales@cckinase.com | United States | 2738 | 58 |
| Absin Bioscience Inc. | 021-38015121 18438616290 | wulan@absin.cn | China | 24731 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 19970 | 58 |
| Sangon Biotech (Shanghai) Co.,Ltd. | 400-821-026 | Sales@sangon.com | China | 55710 | 58 |
View Lastest Price from AldoxorubicinHCl manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2025-04-27 | Aldoxorubicin hydrochloride
1361563-03-2
|
US $57.00-117.00 / mg | 100% | 10g | TargetMol Chemicals Inc. | ||
 |
2025-04-27 | Aldoxorubicin hydrochloride
1361563-03-2
|
US $57.00-117.00 / mg | 100% | 10g | TargetMol Chemicals Inc. |
-
- Aldoxorubicin hydrochloride
1361563-03-2
- US $57.00-117.00 / mg
- 100%
- TargetMol Chemicals Inc.
-
- Aldoxorubicin hydrochloride
1361563-03-2
- US $57.00-117.00 / mg
- 100%
- TargetMol Chemicals Inc.